Mahnken A H
Klinik für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Marburg, Philipps-Universität Marburg, Baldingerstraße, Marburg, Germany.
Radiologe. 2013 Mar;53(3):209-15. doi: 10.1007/s00117-012-2418-9.
CLINICAL/METHODICAL ISSUE: Venous thromboembolism (VTE) is the third most common disease of the cardiovascular system. It is associated with a 30-day lethality in the range of 6 % in deep vein thrombosis and 12 % in pulmonary embolism (PE). There are various guidelines with sometimes controversial recommendations regarding the use of inferior vena cava (IVC) filters.
Implantation of IVC filters is a standard therapy in selected patients with an estimated 259,000 filters implanted in 2012.
Optionally retrievable filters are increasingly being used in clinical routine practice. Future developments will include biodegradable and drug-eluting filters.
When compared to anticoagulation as the reference therapy of VTE, IVC filters will significantly reduce the frequency of symptomatic PE; however, there is no advantage in overall survival for either therapy.
Despite different guidelines in clinical routine practice the use of IVC filters appears to depend on the individual clinical experience and assessment of the interventionalist.
Nowadays retrievable filters should be used although there are relevant differences between the various devices. As a matter of principle all IVC filters should be removed as soon as adequate anticoagulation can be established.
临床/方法学问题:静脉血栓栓塞症(VTE)是心血管系统中第三常见的疾病。深静脉血栓形成的30天致死率在6%左右,肺栓塞(PE)的30天致死率为12%。关于下腔静脉(IVC)滤器的使用,有各种指南,其建议有时存在争议。
IVC滤器植入是特定患者的标准治疗方法,2012年估计植入了259,000个滤器。
可选择性取出的滤器在临床常规实践中越来越多地被使用。未来的发展将包括可生物降解和药物洗脱滤器。
与作为VTE参考治疗的抗凝治疗相比,IVC滤器将显著降低有症状PE的发生率;然而,两种治疗方法在总体生存率方面均无优势。
尽管临床常规实践中有不同的指南,但IVC滤器的使用似乎取决于介入医生的个人临床经验和评估。
如今应使用可取出滤器,尽管各种设备之间存在相关差异。原则上,一旦能够建立充分的抗凝治疗,所有IVC滤器都应取出。